DNAzyme technology and cancer therapy: Cleave and let die
Dass, Crispin R and Choong, Peter F. M and Khachigian, Levon M (2008) DNAzyme technology and cancer therapy: Cleave and let die. Molecular Cancer Therapeutics , 7 (2). pp. 243-251. ISSN 1535-7163Full text for this resource is not available from the Research Repository.
Novel molecules are constantly being discovered and developed to find better means of managing debilitating and fatal diseases, which include cancer in its multiple forms. Among these molecules, and as a direct consequence of a better understanding of the molecular basis of diseases, are those falling within the class of gene therapeutics. Among these players, deoxyribozymes (DNAzymes) have come a long way from being just another analytic tool available to molecular biologists. Recent studies have shown the potential DNAzymes to serve as drugs both in cell-based assays and preclinical models of cancer. It is anticipated that with the development of smart delivery systems for DNAzymes, better pharmacokinetics and pharmacodynamics will be possible, expediting DNAzyme march toward the clinic. Also, the ability of DNAzymes to yield to such phenomena as lightinduced activation may be exploited for targeted therapy. This review documents the rise of DNAzymes in the fight against cancer and serves as a forecast for this promising biotechnology in this context.
|Uncontrolled Keywords:||ResPubID18857. novel molecules, cancer therapy, DNAzymes|
|Subjects:||RFCD Classification > 320000 Medical and Health Sciences
FOR Classification > 1115 Pharmacology and Pharmaceutical Sciences
SEO Classification > 8608 Human Pharmaceutical Products
Faculty/School/Research Centre/Department > School of Biomedical and Health Sciences
|Date Deposited:||14 Sep 2011 04:16|
|Last Modified:||10 Mar 2015 06:17|
|ePrint Statistics:||View download statistics for this item|
|Citations in Scopus:||45 - View on Scopus|
Repository staff only